Thorton Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia, 1215 Lee Street, Charlottesville, VA, 22902, USA.
Curr Treat Options Oncol. 2018 Nov 5;19(12):70. doi: 10.1007/s11864-018-0593-2.
Activity of PD-1 and PD-L1 inhibitors has been demonstrated in ovarian, endometrial, and cervical cancer, with a tolerable side effect profile and the highest response rate seen in mismatch repair-deficient endometrial cancers. Other biomarkers are under active investigation. Tumor testing for mismatch repair deficiency or high microsatellite instability for treatment with pembrolizumab should be considered an option for all women with progressive gynecologic malignancy.
PD-1 和 PD-L1 抑制剂在卵巢癌、子宫内膜癌和宫颈癌中的活性已得到证实，具有可耐受的副作用谱，在错配修复缺陷型子宫内膜癌中观察到最高的反应率。其他生物标志物也在积极研究中。对于所有患有进展性妇科恶性肿瘤的女性，肿瘤检测错配修复缺陷或高微卫星不稳定性以进行 pembrolizumab 治疗应被视为一种选择。
